Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X:
“New Abstract at ESTRO26 ‘Radiographic Response in Patients with Stage III Unresectable Non-Small Cell Lung Cancer Treated with an Intratumoral Radioenhancer (JNJ-90301900)'”
Promising early outcomes from the Phase II CONVERGE study highlight the potential of JNJ-1900 (NBTXR3), a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles. Administered via a one-time intratumoral injection and activated by radiotherapy, the physical mechanism of action is designed to maximize local tumor destruction without increasing systemic toxicity. The study investigates this approach alongside concurrent chemoradiotherapy (cCRT) and consolidative immunotherapy for patients with Stage III unresectable non-small cell lung cancer (NSCLC).
Led by investigators including Benjamin Cooper and Jeffrey Bradley, the trial demonstrated an acceptable safety profile with no serious treatment-emergent adverse events (TEAEs) impacting the patients’ ability to continue their scheduled therapy. Initial efficacy responses from the first seven patients evaluated following cCRT, and prior to anti-PD-L1 administration, revealed a promising Objective Response Rate (ORR) of 71.4% and a Disease Control Rate (DCR) of 100%. These early results significantly exceed the historical estimated benchmark ORR of 45%–50% for standard care.
Read the full abstract details and company updates on Nanobiotix.
Other articles about Radiation Oncology on OncoDaily.